Developing first-in-class therapeutics based on cutting-edge science:

ExomeresTM by Exopharm.

 

Therapeutic ExomeresTM

from Stem Cells

Exomeres are biological nanoparticles naturally secreted by stem cells. They are produced using Exopharm’s proprietary LEAP process, which delivers a unique blend of exosomes / vesicles with high-yield.


Exomeres are a cell-free super-drug with the potential to treat a range of conditions such as osteoarthritis, eye disease and fibrosis as a regenerative medicine.


Exomeres carry a rich molecular cargo of nucleic acids, lipids and proteins and are taken up by cells inside the body.


Harnessing natural mechanisms, Exomeres transfer information, energy and cell building materials between cells that promote tissue repair, healing and regeneration

Advancing knowledge in stem-cell therapy is demonstrating that positive medical outcomes can be achieved even without using the therapeutic cells themselves. Instead, the essential therapeutic components are the cell-secreted extracellular vesicles (EVs), including exosomes.


It has become apparent that these EVs alone are sufficient to deliver beneficial effects in models of disease – by efficient delivery of the information, machinery and energy to drive repair programs in damaged tissues. While delivering the therapeutic benefits, Exomeres offer a range of advantages over the use of cells for therapy. Being cell-free, they are easy to transport and deliver to patients around the world. Exomeres also cause less concern over their safety as they are not living cells: they have much more pharmaceutical properties and will not remain in the body for extended periods.


Exomeres – a completely new class of biological therapeutic.

Exopharm is investing in the pharma-grade manufacturing process and preclinical development of Exomeres to enable first clinical trials for the treatment of joint conditions, eye disease and fibrosis.

News

Press Release: Disruptive technology for regenerative medicine takes a further step

Another Australian first for Melbourne-based Exopharm as it finalized testing and lodged the complete specification for its disruptive LEAP technology – a further step in bringing extracellular vesicles as an acellular therapy to treat patients with degenerative conditions. The medical need for innovative, safe and effective regenerative medicines have largely not been met by using cells such as adult stem cells – despite significant investment and decades of clinical trials. Our aging population has problems such as osteoarthritis, chronic wounds, fibrosis, diabetes and vascular disease, and patient groups are pushing for new treatments to be brought forward. But...
Read More

Exopharm Q&A with Jason Howitt, neurobiologist at Swinburne University of Technology and the Florey Institute of Neuroscience and Mental Health in Melbourne

Exosomes could be critical players in the onset of Parkinson’s and other neurodegenerative disorders, says Jason Howitt What’s the focus of your research? For our exosome research, the main focus is Parkinson’s disease and related neurodegenerative disorders. Parkinson’s disease is associated with the formation in the brain of misfolded clumps of a protein called α-synuclein. We’ve found a way that α-synuclein is packaged inside exosomes, and we’ve been studying how that can affect the brain to cause the disease. The other focus we have is how exosomes work in the body in general – how they move in the body, where they can move to, and what they do. As a neurobiologist, what first...
Read More

Exosomes linking obesity and diabetes

Exosomes from lean individuals can reverse the symptoms of diabetes associated with obesity, a new animal study shows Inflammatory exosomes are the missing link by which obesity causes type 2 diabetes, researchers from the University of California San Diego have shown. The discovery could lead to earlier diabetes diagnosis and new ways to treat the disease, the researchers say. Overweight or obese individuals have a heightened risk for several health conditions, including type 2 diabetes. In fact, obesity is the most common cause of the disease. Patients with diabetes are insulin resistant, which means their body can no longer keep its blood glucose levels in check. As a result,...
Read More

Our Team.

Dr. Ian Dixon

CEO

linkedin

Dr. Gregor Lichtfuss

COO

twitter linkedin

Dr. Jim Palmer

Drug Development

linkedin

Melbourne - Australia